Geographic Atrophy Secondary to Age-related Macular Degeneration study: ADX-038
Official title Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
ClinicalTrials.gov ID: NCT06990269
What this study is testing
What is ADX-038?
ADX-038 is an investigational siRNA drug being studied for geographic atrophy secondary to age‑related macular degeneration.
Also referred to as siRNA.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study will see if ADX‑038 helps treat geographic atrophy and will also look at safety and how the drug behaves in the body.
- Who it's for
- It is looking for adults who have geographic atrophy caused by age‑related macular degeneration.
- What's involved
- Participants will receive either ADX‑038 or a placebo and will have eye exams and other tests to monitor the condition and the drug’s effects.
- Time commitment
- The study lasts several months and requires regular clinic visits for eye exams and safety monitoring.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 60 and older
You may be able to join if
- Clinical diagnosis of GA of the macula secondary to AMD
- GA lesions between 2.5 and 12.5 mm2 at screening
- Sufficiently clear ocular media, adequate pupillary dilation and fixation to permit quality fundus imaging in the study eye as described in the...
- Willing and able to comply with clinic visits and study-related procedures, including completion of the full series of meningococcal vaccinations and...
You likely can't join if
- Has GA secondary to causes other than AMD
- Has active ocular disease that compromises or confounds visual function
- History of surgery for retinal detachment
- Has ocular condition other than GA secondary to AMD
- Use of intravitreal complement inhibitors in study eye
- Hereditary or acquired complement deficiency
See the full eligibility criteria
- Clinical diagnosis of GA of the macula secondary to AMD
- GA lesions between 2.5 and 12.5 mm2 at screening
- Sufficiently clear ocular media, adequate pupillary dilation and fixation to permit quality fundus imaging in the study eye as described in the protocol
- Willing and able to comply with clinic visits and study-related procedures, including completion of the full series of meningococcal vaccinations and pneumococcal vaccination required per protocol
- Has GA secondary to causes other than AMD
- Has active ocular disease that compromises or confounds visual function
- History of surgery for retinal detachment
- Has ocular condition other than GA secondary to AMD
- Use of intravitreal complement inhibitors in study eye
- Hereditary or acquired complement deficiency
- Active viral, bacterial or fungal infection
- Liver injury as evidenced by abnormal liver function tests
- Donating blood
- History of choroidal neovascularization in the study eye
The study team makes the final eligibility decision.
Where it is enrolling
- Gilbert, Arizona, United States
- Phoenix, Arizona, United States
- Bakersfield, California, United States
- Beverly Hills, California, United States
- Huntington Beach, California, United States
- Poway, California, United States
- Walnut Creek, California, United States
- Orlando, Florida, United States
- Wildwood, Florida, United States
- Hagerstown, Maryland, United States
- Reno, Nevada, United States
- Austin, Texas, United States
- Bellaire, Texas, United States
- Dallas, Texas, United States
- McAllen, Texas, United States
- Round Rock, Texas, United States
- San Antonio, Texas, United States
- The Woodlands, Texas, United States
- St. George, Utah, United States
- Albury, New South Wales, Australia
+ 17 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 60 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Gilbert, Arizona, United States; Phoenix, Arizona, United States; Bakersfield, California, United States; Beverly Hills, California, United States; Huntington Beach, California, United States; Poway, California, United States and 31 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.